THERAPEUTIC TARGETING OF CATHEPSIN C « From Pathophysiology to Treatment »
The International Symposium ISyCatC II will focus on the targeting of cathepsin C, a protease that activates most of tissue-degrading proteases during inflammatory diseases such as COPD, cystic fibrosis, bronchiectasis, granulomatosis with polyangiitis or rheumatoid arthritis. Cathepsin C thus appears as a potential therapeutic target to impair protease-driven tissue degradation in chronic inflammatory diseases.
This symposium will bring together for the second time the world leading specialists from academic labs and industry, working on cathepsin C and its target enzymes. It will associate biochemists studying the functionality of cathepsin C, cell biologists studying its maturation and tissue localization, chemists developing specific cathepsin C inhibitors and clinicians studying the pathologies in which cathepsin C is directly or indirectly involved.
